Drug Trial Radar · NCT06497491
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Dec 12, 2023
Primary completion
May 29, 2025
Study completion Jul 10, 2025
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized single-blind comparative parallel group study of the efficacy and safety of canakinumab biosimilar GNR-086 (JSC \"GENERIUM\", Russia) and Ilaris® (Novartis Pharma Stein AG, Switzerland) in the treatment of patients with adult-onset Still\'s disease. Participants will receive a subcutaneous canakinumab 4 mg/kg every 4 weeks. The treatment duration is 24 weeks following with the study extension.
Conditions
- Still's Disease Adult Onset
Interventions
GNR-086Biological
GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
Ilaris®Biological
Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with a clinically significant (>1.2 points) decrease in the Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS28-ESR)Time frame: Week 12
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital"
Chelyabinsk, Chelyabinsk Oblast, Russia
Limited Liability Company "Medical Center "Revma-Med"
Kemerovo, Kemerovo Oblast, Russia
Limited Liability Company "OLLA-MED"
Moscow, Moscow, Russia
Federal State Budgetary Institution "Research Institute of Rheumatology named after V.A. Nasonova"
Moscow, Moscow, Russia
State budgetary healthcare institution of the city of Moscow "City Clinical Hospital No. 52 of the Moscow Health Department" (GBUZ "City Clinical Hospital No. 52 DZM")
Moscow, Moscow, Russia
Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N. I. Pirogova
Moscow, Moscow, Russia
Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N.I. Pirogov Ministry of Health of Russia Separate structural unit "Russian Gerontological Scientific and Clinical Center"
Moscow, Moscow, Russia
Limited Liability Company "Medical Center "Healthy Family"
Novosibirsk, Novosibirsk Oblast, Russia
Federal State Budgetary Educational Institution of Higher Education Orenburg State Medical University of the Ministry of Health of Russia
Orenburg, Orenburg Oblast, Russia
Limited Liability Company "Medical Technologies" LLC "Medical Technologies"
Saint Petersburg, Sankt-Peterburg, Russia
Limited Liability Company "Ex Seven Clinical Research"
Saint Petersburg, Sankt-Peterburg, Russia
Limited Liability Company "Interleukin"
Saint Petersburg, Sankt-Peterburg, Russia
State Budgetary Healthcare Institution Leningrad area Clinical Hospital
Saint Petersburg, Sankt-Peterburg, Russia
Private foundation "RZD-Medicine" Smolensk"
Smolensk, Smolensk Oblast, Russia
Limited Liability Company "BioMed"
Vladimir, Vladimirskaya Oblast’, Russia
State health care institution city clinical hospital №25
Volgograd, Volgograd Oblast, Russia
State Budgetary Healthcare Institution "Clinical Hospital No. 2"
Yaroslavl, Yaroslavl Oblast, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.